XOMA Royalty (NASDAQ:XOMA) Rating Lowered to Hold at Wall Street Zen

Wall Street Zen lowered shares of XOMA Royalty (NASDAQ:XOMA - Free Report) from a buy rating to a hold rating in a research report report published on Saturday.

Several other research analysts have also issued reports on XOMA. HC Wainwright reaffirmed a "buy" rating and issued a $104.00 target price on shares of XOMA Royalty in a research note on Wednesday, May 28th. Benchmark initiated coverage on shares of XOMA Royalty in a research note on Thursday, April 17th. They issued a "buy" rating and a $35.00 target price on the stock.

XOMA Royalty Price Performance

NASDAQ:XOMA traded up $0.17 during mid-day trading on Friday, reaching $27.49. 269,597 shares of the company were exchanged, compared to its average volume of 34,967. XOMA Royalty has a 12 month low of $18.35 and a 12 month high of $35.00. The company has a fifty day moving average of $25.00 and a 200 day moving average of $24.30. The company has a quick ratio of 5.54, a current ratio of 5.54 and a debt-to-equity ratio of 1.18. The stock has a market cap of $329.06 million, a PE ratio of -23.90 and a beta of 0.94.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.32. XOMA Royalty had a negative net margin of 13.04% and a negative return on equity of 12.43%. The firm had revenue of $15.91 million for the quarter, compared to analyst estimates of $6.75 million. On average, research analysts anticipate that XOMA Royalty will post -1.41 EPS for the current fiscal year.

Insider Activity

In related news, CIO Bradley Sitko bought 2,000 shares of the company's stock in a transaction on Monday, April 7th. The shares were purchased at an average cost of $24.70 per share, for a total transaction of $49,400.00. Following the acquisition, the executive now owns 5,045 shares of the company's stock, valued at approximately $124,611.50. This represents a 65.68% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the firm's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $27.10, for a total transaction of $10,642,793.30. Following the sale, the insider now owns 1,267,545 shares in the company, valued at $34,350,469.50. This trade represents a 23.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have acquired 25,178 shares of company stock valued at $636,300. 9.10% of the stock is currently owned by insiders.

Institutional Trading of XOMA Royalty

Several hedge funds have recently bought and sold shares of XOMA. GAMMA Investing LLC raised its holdings in shares of XOMA Royalty by 1,063.8% in the first quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 1,585 shares during the last quarter. New York State Common Retirement Fund raised its holdings in shares of XOMA Royalty by 51.2% in the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock valued at $62,000 after purchasing an additional 800 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of XOMA Royalty by 38.0% in the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock valued at $113,000 after purchasing an additional 1,183 shares during the last quarter. Deutsche Bank AG raised its holdings in shares of XOMA Royalty by 5,087.9% in the first quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock valued at $128,000 after purchasing an additional 6,309 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of XOMA Royalty by 34.7% in the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock valued at $205,000 after purchasing an additional 2,009 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.